▲ +82.47% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Mirum Pharmaceuticals in the last 3 months. The average price target is $40.60, with a high forecast of $52.00 and a low forecast of $30.00. The average price target represents a 82.47% upside from the last price of $22.25.
The current consensus among 6 contributing investment analysts is to buy stock in Mirum Pharmaceuticals.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its lead product candidate is maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. The company is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was founded in 2018 and is headquartered in Foster City, California.